3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Glioblastoma
18
Brain Neoplasms
8
Lymphoma
6
Central Nervous System Neoplasms
6
Medulloblastoma
4
Glioma
4
Astrocytoma
4
Recurrence
3
Neoplasms
2
Lymphoma, Non-Hodgkin
2
Lymphoma, AIDS-Related
2
Lung Neoplasms
2
Uveal Melanoma
1
Spinal Cord Neoplasms
1
Solid Tumor
1
Sarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Neoplasm Metastasis
1
Melanoma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Leukemia-Lymphoma, Adult T-Cell
1
Kidney Neoplasms
1
Intraocular Lymphoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Gliosarcoma
1
Interventions
Rituximab
8
Cyclophosphamide
8
Peripheral Blood Stem Cell Transplantation
7
Methotrexate
7
fludarabine phosphate
6
Whole-Body Irradiation
5
Tacrolimus
5
Mycophenolic Acid
5
Dexamethasone
5
Cyclosporine
5
Cytarabine
4
Transplantation
3
Radiotherapy
3
Filgrastim
3
Busulfan
3
pegfilgrastim
2
merphos
2
etoposide phosphate
2
Methylprednisolone
2
Lenalidomide
2
Granulocyte Colony-Stimulating Factor
2
Etoposide
2
Carboplatin
2
Calcium Dobesilate
2
Antilymphocyte Serum
2
zanubrutinib
1
sodium thiosulfate
1
sargramostim
1
oblimersen
1
ibrutinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Intraocular Lymphoma
×
Lomustine
×
Clear all
NCT00074191
2017-04-21
Protocol-A
OHSU Knight Cancer Institute
Phase 2
Completed
1 enrolled